Deciphera Pharmaceuticals (NASDAQ:DCPH) Earns Neutral Rating from Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. initiated coverage on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a research report report published on Monday morning, The Fly reports. The brokerage issued a neutral rating on the stock.
A number of other analysts have also recently commented on DCPH. ValuEngine raised shares of Deciphera Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, August 3rd. Barclays reissued a buy rating and set a $85.00 target price (up previously from $80.00) on shares of Deciphera Pharmaceuticals in a research note on Monday, May 18th. Zacks Investment Research lowered shares of Deciphera Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, July 29th. SVB Leerink lowered their price target on shares of Deciphera Pharmaceuticals from $55.00 to $54.00 and set a market perform rating on the stock in a research report on Wednesday, August 5th. Finally, SunTrust Banks boosted their price target on shares of Deciphera Pharmaceuticals from $82.00 to $91.00 and gave the stock a buy rating in a research report on Monday, May 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $70.86.
DCPH stock opened at $52.57 on Monday. The stock has a market capitalization of $2.96 billion, a P/E ratio of -10.21 and a beta of 1.84. The firm has a 50-day simple moving average of $46.17 and a 200-day simple moving average of $49.92. The company has a quick ratio of 12.30, a current ratio of 12.33 and a debt-to-equity ratio of 0.02. Deciphera Pharmaceuticals has a 52 week low of $31.37 and a 52 week high of $71.11.
In other news, CFO Thomas Patrick Kelly sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $47.71, for a total value of $143,130.00. Following the transaction, the chief financial officer now directly owns 13,040 shares in the company, valued at approximately $622,138.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael Douglas Taylor sold 27,544 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $55.22, for a total transaction of $1,520,979.68. Following the completion of the transaction, the director now owns 49,211 shares in the company, valued at $2,717,431.42. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 108,330 shares of company stock worth $5,966,578. Company insiders own 3.81% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in DCPH. BlackRock Inc. increased its stake in Deciphera Pharmaceuticals by 5.4% during the 1st quarter. BlackRock Inc. now owns 2,127,101 shares of the company’s stock worth $87,571,000 after buying an additional 108,024 shares during the period. SG Americas Securities LLC increased its stake in Deciphera Pharmaceuticals by 46.6% during the 1st quarter. SG Americas Securities LLC now owns 4,360 shares of the company’s stock worth $180,000 after buying an additional 1,385 shares during the period. Victory Capital Management Inc. increased its stake in Deciphera Pharmaceuticals by 8.9% during the 1st quarter. Victory Capital Management Inc. now owns 45,090 shares of the company’s stock worth $1,856,000 after buying an additional 3,691 shares during the period. Arizona State Retirement System purchased a new stake in Deciphera Pharmaceuticals during the 1st quarter worth approximately $247,000. Finally, New York State Common Retirement Fund increased its stake in Deciphera Pharmaceuticals by 54.5% during the 1st quarter. New York State Common Retirement Fund now owns 28,742 shares of the company’s stock worth $1,183,000 after buying an additional 10,142 shares during the period. 74.63% of the stock is currently owned by hedge funds and other institutional investors.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Recommended Story: Intrinsic Value and Stock Selection
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.